Observations placeholder

Temozolomide, (TMZ) (brand names Temodar and Temodal and Temcad) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.

Side-effects

The most common non-hematological adverse effects associated with temozolomide - nausea and vomiting - are either self-limiting or readily controlled with standard antiemetic therapy. These effects are usually mild to moderate (grade 1 to 2). The incidence of severe nausea and vomiting is around 4% each. Patients who have pre-existing or a history of severe vomiting may require antiemetic therapy before initiating temozolomide treatment. Temozolomide should be administered in the fasting state, at least one hour before a meal. (Capsules must not be opened or chewed, but swallowed whole with a glass of water.) Antiemetic therapy may be administered prior to, or following, administration of temozolomide. Temozolomide is contraindicated in patients with hypersensitivity to its components or to dacarbazine. The use of temozolomide is not recommended in patients with severe myelosuppression.

Temozolomide is genotoxic, teratogenic and fetotoxic and should not be used during pregnancy. Lactating women should discontinue nursing while receiving the drug because of the risk of secretion into breast milk. One study indicated that women that have taken temozolomide without concomitant fertility preservation measures achieve pregnancy to a lesser rate later in life, but the study was too small to show statistical significance in the hypothesis that temozolomide would confer a risk of female infertility In male patients, temozolomide can have genotoxic effects. Men are advised not to father a child during or up to six months after treatment and there is the possibility of irreversible infertility due to temozolomide therapy.

Temozolomide can cause acute respiratory failure.

On Jan, 21, 2016: 2,775 people reported to have side effects when taking Temodar. Among them, 20 people (0.72%) have Hallucination.

Time on Temodar when people have Hallucination  :

Gender of people who have Hallucination when taking Temodar  :

Age of people who have Hallucination when taking Temodar  :

Severity of Hallucination when taking Temodar  :

On Feb, 5, 2016: 2,775 people reported to have side effects when taking Temodar. Among them, 237 people (8.54%) have Death.

Time on Temodar when people have Death :